Rational approach to the treatment of EGFR-positive lung cancer
Molecularly targeted therapy with tyrosine kinase inhibitors (TKI) has been recognized as the optimal treatment option for patients with EGFR-positive non-small-cell lung cancer (NSCLC). At present, 5 drugs of this group are available: first generation – erlotinib and gefitinib, second generation –...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado em: |
Remedium Group LLC
2019-12-01
|
| coleção: | Медицинский совет |
| Assuntos: | |
| Acesso em linha: | https://www.med-sovet.pro/jour/article/view/5146 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|